Primary Lateral Sclerosis Treatments
Find Primary Lateral Sclerosis Treatments
Medications for Primary Lateral Sclerosis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Primary Lateral Sclerosis.
Found 5 Approved Drugs for Primary Lateral Sclerosis
Riluzole
Brand Names
Tiglutik, Teglutik
Riluzole
Brand Names
Tiglutik, Teglutik
Form: Tablet, Liquid
Method of administration: Oral
FDA approval date: June 18, 2013
Classification: Benzothiazole
Riluzole is indicated for the treatment of amyotrophic lateral sclerosis (ALS). Riluzole is indicated for the treatment of amyotrophic lateral sclerosis (ALS) ( 1 )
Radicava
Generic Name
Edaravone
Radicava
Generic Name
Edaravone
Form: Injection, Kit
Method of administration: Intravenous
FDA approval date: May 05, 2017
Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS). Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS). ( 1 )
Zolgensma
Generic Name
Onasemnogene Abeparvovec-Xioi
Zolgensma
Generic Name
Onasemnogene Abeparvovec-Xioi
Form: Kit
FDA approval date: May 24, 2019
ZOLGENSMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. Limitations of Use The safety and effectiveness of repeat administration of ZOLGENSMA have not been evaluated [see Adverse Reactions.
Qalsody
Generic Name
Tofersen
Qalsody
Generic Name
Tofersen
Form: Injection
Method of administration: Intrathecal
FDA approval date: April 25, 2023
Classification: Antisense Oligonucleotide
QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). QALSODY is an antisense oligonucleotide indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). ( 1 )
Itvisma
Generic Name
Onasemnogene Abeparvovec-brve
Itvisma
Generic Name
Onasemnogene Abeparvovec-brve
Form: Injection
Method of administration: Intrathecal
FDA approval date: November 24, 2025
ITVISMA is indicated for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in survival motor neuron 1 (SMN1) gene. ITVISMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in SMN1 gene. ( 1 )
Showing 1-5 of 5
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances